Arbutus Biopharma (ABUS) Retained Earnings (2010 - 2026)

Arbutus Biopharma has disclosed Retained Earnings across 17 years of filings, most recently posting -$48.2 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$48.2 million, changed 0.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$48.2 million (changed 0.06% YoY), and the FY2025 annual result was -$1.4 billion, down 2.49% from the prior year.
• Retained Earnings came in at -$48.2 million for Q1 2026 at Arbutus Biopharma, up from -$1.4 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$48.1 million in Q3 2025 to a low of -$1.4 billion in Q4 2025.
• The 5-year median for Retained Earnings is -$49.6 million (2023), against an average of -$489.2 million.
• Across the five-year window, Retained Earnings plunged 2680.97% in 2024 and jumped 96.39% in 2025, its largest moves.
• Arbutus Biopharma's Retained Earnings stood at -$50.5 million in 2022, then grew by 4.09% to -$48.4 million in 2023, then slumped by 2680.97% to -$1.3 billion in 2024, then slipped by 2.49% to -$1.4 billion in 2025, then soared by 96.51% to -$48.2 million in 2026.
• The last three Retained Earnings figures came in at -$48.2 million (Q1 2026), -$1.4 billion (Q4 2025), and -$48.1 million (Q3 2025), per Business Quant data.